Since the first publications of Fisher 1 and Evans, 2 the combination of autoimmune haemolytic anaemia (AIHA) and thrombocytopenic purpura (AITP) has been known as the Evans syndrome 3 (ES). This combination, besides often heralding a more systemic autoimmune disease such as SLE, 4 is generally harder to treat and more refractory than the single entities. It is no wonder, then, that new aggressive approaches founded on powerful immunosuppression (generally defined as immuno-ablation) followed, or not, by stem cell rescue or genuine transplantation have been utilized recently for severe autoimmune diseases [5] [6] [7] (SADs), including refractory ES and refractory autoimmune thrombocytopenic purpura (AITP). Owing to the rarity of both conditions, and more particularly of ES, only single cases have been published up to now, with what appear to be rather controversial results. Many, if not most of these cases have been published in this journal, so that the time has come for an interim evaluation and some comments.
The most interesting and stimulating report comes from Salt Lake City, where a 5-year-old boy affected from infancy by an aggressive, relapsing and life-threatening ES was successfully transplanted with HLA-identical sibling cord blood. 8 The conditioning regimen consisted of TBI (1350 cGy over 6 days) followed by CY 120 mg over 2 days. There was good engraftment, aGVHD (ungraded), clinical remission and total negativisation of Coombs tests (DAT and IAT) at the end of follow-up. Most regrettably this patient died of acute liver failure 9 months post transplant. The second comes from Chicago where a patient with ES is 4 months post transplant with 100% donor haematopoiesis, no GVHD and complete regression of anti-erythrocyte and platelet antibodies (RK Burt, personal communication).
It is well known that, because of the greater safety of autologous transplants, this procedure has been utilized worldwide for severe autoimmune diseases, 6 including ES. Mobilised peripheral stem and progenitor cells (PBSC) have been preferred. However, in a 25-year-old female with ES mobilization with the routine doses of 4 g/m 2 CY and G-CSF was followed by exacerbation of haemolysis and thrombocytopenia, and the patient died on day 16 of an intracranial haemorrhage. 9 The authors postulate that an inhibition of haematopoiesis without a concomitant (and sufficient) decline of autoimmunity may have caused this unfortunate termination. It is regrettable that no mention is made of the direct antiglobulin test (DAT/Coombs), or of the bone marrow aspirate after CY.
A more fortunate patient has been reported recently. 10 She was a 17-year-old girl who 4 years previously had suffered with deep venous thrombosis, had both antiphospholipid (APL) and antinuclear (ANA homogenous, antidsDNA) antibodies and developed a very severe recurrent ES. PBSC were mobilised with CY (4 g/m 2 ) and G-CSF, and the patient was conditioned with CY (100 mg/day/2 days), ATG and methylprednisolone. Eight months later the patient was in a steroid-free complete remission, with residual borderline ANA and DAT.
Finally, a 31-year-old splenectomised male with refractory ES was treated with the immunoablative regimen (CY 200 mg/kg) without SC rescue utilized at Johns Hopkins University School of Medicine, 11 and went into a good partial remission, with persistent (but not extreme) thrombocytopenia and positive DAT. 12 Refractory AITP is defined as no response to, or relapse after splenectomy, unresponsiveness to corticosteroids at standard doses, and need for further treatment because of recurrent haemorrhagic symptoms and/or unsafe platelet levels. 13, 14 Four 'levels of therapy' have been recently defined by McMillan, 14 but none may be successful in markedly refractory patients. Four cases in the literature have shown failure after immunosuppressive conditioning followed by autologous SC rescue [15] [16] [17] although complete, steroid-independent remissions were obtained in the first two patients for over 1 year. 14 The two cases treated with HD-CY at Johns Hopkins died of haemorrhagic complications after brief remissions.
It is, of course, quite impossible to reach evidence-based recommendations, 18 since cases are few and results controversial. Nevertheless, similarly to the recommendations issued by the American Society of Hematology, 19, 20 some general comments can be made.
When treating these difficult patients, especially the ones with simultaneous intense haemolysis plus haemorrhagic thrombocytopenia, attempts at high-dose immunosuppressive chemotherapy followed by ASCT are amply justified. Certainly, interesting results have also been reported utilising cyclosporin 21 and/or liposomal doxorubicin. 22 However it remains to be seen whether long-term results will prove superior, especially in these predominantly B cell-mediated diseases, 23 which are displaying an unexpected refractoriness even to high-dose immunosuppression.
The prevailing perceptions of autoimmunity dictate that stable cures can only be expected when the patient's autoreactive cells are replaced with cells of a healthy donor who is not susceptible to whatever factors that break tolerance. 24 It is indeed regrettable, for this area of autoimmunity, that the final outcome of the patient transplanted with allogeneic cord blood after a powerful combined conditioning regimen could not be ascertained because of intercurrent disease. 8 In autologous transplants reprogramming of the immune system has been proposed, 25 but both relapses and the studies of immune reconstitution (reviewed in Ref. 7) make this hypothesis doubtful. That the main therapeutic effect is mediated by intense immunosuppression is now confirmed by the Johns' Hopkins results. 11, 12 In conclusion, intense autoimmune suppression is necessary. 26 However, this may be obtained also in a less concentrated way.
The treatment with high doses of CY plus steroids (eg 3-4 abs g of each in an induction course), followed by 2 g abs monthly for not less than 6 months, has been efficacious in my own recent experience of four cases (two Evans, two AITP). Although ultimately needed, rigorously designed clinical studies in order to supplement and succeed anecdotal observations and descriptions of case series are recommended. However it seems appropriate to discuss these problems in this journal, in order to make SC transplanters, constantly obsessed by biostatistical studies on neoplastic blood diseases and severe aplastic anaemia, aware of the challenges posed by severe autoimmune diseases of the peripheral blood. 
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